Physician profile
Jules Victor
NPI 1306845029
$3,816.06
in general payments reported to CMS, 2019-2025
39 companies · $788 in 2025
The $788 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $352 · 2020: $291 · 2021: $535 · 2022: $573 · 2023: $606 · 2024: $671 · 2025: $788.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,064.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,064.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $554.12 | 2019-2025 | |
| Novo Nordisk INC | $469.97 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $423.84 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $263.09 | 2019-2025 | Repatha, Otezla, Otezla |
| Viiv Healthcare Company | $260.76 | 2024-2025 | Dovato, Apretude, Rukobia |
| Allergan, INC. | $218.69 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $143.23 | 2022-2024 | Jardiance |
| Merck Sharp & Dohme LLC | $139.52 | 2022-2025 | Zerbaxa, Recarbrio, Dificid |
| Abbvie INC. | $137.89 | 2021-2023 | Qulipta, Ubrelvy |
| Pfizer INC. | $134.69 | 2020-2021 | |
| Dexcom, INC. | $126.09 | 2024-2025 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $101.75 | 2021-2025 | |
| Esperion Therapeutics, INC. | $75.90 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $67.05 | 2021-2025 | Farxiga |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $60.57 | 2019-2023 | Trulance, Xifaxan |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jules Victor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.